Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 27;61(1):e01243-16.
doi: 10.1128/AAC.01243-16. Print 2017 Jan.

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure

Deanna J Buehrle  1 , Ryan K Shields  1   2 , Lloyd G Clarke  3 , Brian A Potoski  3 , Cornelius J Clancy  4   2   5 , M Hong Nguyen  1   2
Affiliations

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure

Deanna J Buehrle et al. Antimicrob Agents Chemother. .

Abstract

We reviewed 37 patients treated for bacteremia due to carbapenem-resistant (CR) Pseudomonas aeruginosa Although 65% of isolates were multiple-drug resistant, therapeutic options were available, as all were susceptible to ≥1 antibiotic. A total of 92% of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 h). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. The Pitt bacteremia score (P = 0.046) and delayed active therapy (P = 0.027) were predictive of death and microbiologic failure, respectively.

Keywords: Pseudomonas aeruginosa; bacteremia; carbapenem resistance; mortality.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Percentage of Carbapenem-resistant P. aeruginosa bloodstream isolates susceptible to tested antibiotics. *, susceptibility rates were defined by CLSI interpretive criteria for P. aeruginosa. All 37 isolates were tested against each antibiotic listed.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:1–7. - PMC - PubMed
    1. Maechler F, Pena Diaz LA, Schroder C, Geffers C, Behnke M, Gastmeier P. 2015. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection 43:163–168. doi:10.1007/s15010-014-0701-6. - DOI - PubMed
    1. Hasanin A, Eladawy A, Mohamed H, Salah Y, Lotfy A, Mostafa H, Ghaith D, Mukhtar A. 2014. Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt. Pan Afr Med J 19:177. - PMC - PubMed
    1. Lyman M, Walters M, Lonsway D, Rasheed K, Limbago B, Kallen A. 2015. Notes from the field: carbapenem-resistant Enterobacteriaceae producing OXA-48-like carbapenemases—United States, 2010–2015. MMWR Morb Mortal Wkly Rep 64:1315–1316. doi:10.15585/mmwr.mm6447a3. - DOI - PubMed
    1. Muscarella LF. 2014. Risk of transmission of carbapenem-resistant Enterobacteriaceae and related “superbugs” during gastrointestinal endoscopy. World J Gastrointest Endosc 6:457–474. doi:10.4253/wjge.v6.i10.457. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources